Showing 2671 results
-
Press Release /Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
-
Press Release /Global survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1] Nearly half (45%) have been asked if they are contagious while 55% do not…
-
Press Release /Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
-
Press Release /The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the…
-
Press Release /In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
-
Press Release /Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience…
-
Press Release /Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
-
Press Release /Chiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux…
-
Press Release /Der Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%…
-
Press Release /Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…